

Sequencing therapy for the relapsed/refractory CLL

Florence CYMBALISTA Hematology Biology, Hopital Avicenne INSERM UMR978, Université Paris13

France








Evaluate the need for treatment

- Is it time to re-treat?
- IWCLL guidelines:
 - Second- and subsequent-line treatment decisions should generally follow the same indications as those used for first-line treatment.
 - For patient who did not achieve good response it is reasonable to initiate second-line treatment without waiting for formal disease progression to be manifest.
 - The rate of disease progression after some newer therapies can be rapid; it can be acceptable to initiate subsequent therapy before formal progression

Strategies in relapsed CLL : ESMO guidelines 2017

- Relapse post chemo
- 2 parameters are considered:
 - Presence of TP53 alteration
 - Early versus late relapse
- Basically: BCR inhibitors possible in every situation
- Late relapse TP53 wild type :
 - Chemo still discussed



Eichhorst, Ann Oncol 2017

Targeted therapies in R/R trials

Ibrutinib

Trials

- RESONATE (Ibru vs ofa)
- HELIOS (BR vs IBR)

Idelalisib (+ R)

Trials

Phase 3 (R-Idela vs rituximab)

Venetoclax

- V+R after CIT
 - MURANO trial
- V after BCRi failureM1432 trial


Real life data

Real life data

Real life data


Results outside of trials are good but never as good as in clinical trials

Ibrutinib in relapsed CLL | RESONATE trial



- ORR 91% in the ibrutinib arm
- Inferior PFS if prior therapies ≥ 2
- 56% of pts still on ibrutinib at 44 months

Ibrutinib for relapsed 17p




Outcomes in 230 patients with relapsed/refractory del(17p) CLL/SLL from three ibrutinib studies.

- Median follow-up of 28 months
- Overall response rate was 85%
- Estimated 30-month PFS was 57%

J Jones Br J Haematol.2018


Ibrutinib + chemo? I-BR vs BR / HELIOS trial



I-BR (vs BR) in R/R CLL without 17p del

Median follow-up 34.8 months

- Median PFS NR vs 14.8 months
- 36-month PFS 68 % vs 13.9 %
- MRD(-) 26.3 % vs 6.2 %



No direct comparison with ibrutinib alone Not indicated for TP53 alterations


Fraser, Leukemia 2019

Safe Ibrutinib use


- In theory, ibrutinib may be indicated for control of CLL in all relapsed settings
 after immunochemotherapy
- But rather than CLL characteristics, decision to use ibrutinib is driven by the risk of adverse events and drug interactions
- Ibrutinib treatment decision should include
 - Cardiovascular risk assessment
 - Extensive analysis of co-medications
 - CYP3A4 inducers and inhibitors, anticoagulants, antiplatelet therapy+++
 - Understanding and willingness to follow long term therapy
- It is important to raise awareness of treating physician and patient on adverse events and comedications


Resistance to Ibrutinib

- Ibrutinib is used as a prolonged monotherapy until progression
- Resistance mutations occur, notably after 3 years
 - mostly located at C481S Btk
 - PLCγ2 mutations may also occur
 - In a recent snapshot study of patients on ibrutinib for 3 years we observed that
 - Half of the patients were in very good response,
 - Among the other half, 17/30 had a Btk mutations, and 14/17 progressed within 9 months, whereas only 2 /13 progressed in the absence of mutations



Idela + R: relapse after chemoimmunotherapy






Results of the pivotal phase 3 trial Idela + R versus placebo + R alone

Elderly patients Several lines, comorbidities Presence of del(17p) or TP53 mutations did not negatively affect clinical outcome


Mediane OS 40,6 vs 34,6 months Cross over allowed



Long term PFS Idela+R with and without TP53 alteration

Sharman JP, JCO 2019;

Venetoclax in R/R CLL: VR vs BR (MURANO trial)




Median follow-up 36 months


Kater A, JCO 2019

VR vs BR (MURANO) | MRD and PFS

PFS from venetoclax discontinuation



- Median follow-up 9.9 months post treatment
- 1y-PFS 87% (95% CI 81.1-93.8)
- Predictive factors for relapse
 - TP53 abnormalities
 - Absence of 11q deletion
 - MRD (blood) at M24



Correlation between MRD and PFS

Kater A, JCO 2019


Venetoclax and BCL2 mutations

- 15 pts progressing on venetoclax
- Targeted sequencing (33 genes)
 - before venetoclax
 - at relapse
- BCL2 mutations
 - 7/15 pts
 - reduces the affinity of venetoclax to BCL2

Blombery, Cancer Discovery 2019

- 3 of 4 patients with >3 years on drug and refractory disease are mutated in BCL2
- Another mutation D103Y identified
- Preceding the G101V in one patient
- The 2 mutations were present in 2 different subclones

Tausch, Hematologica 2019




First relapse after chemotherapy: I or V+R?

- Provided we have access to both therapies
- Some similar arguments
 - Clinical trials results
 - Oral therapy
 - Efficient in unfavorable risk groups
- Ibrutinib
 - Caution with comorbidities/comed
 - Various adverse events
 - Prolonged therapy
 - Long term data available
 - Developpement of resistances

- Venetoclax + R
 - Ramp up and hospitalization
 - Neutropenias
 - Fixed duration therapy
 - No long term data available,
 - Developpement of resistances
- Decision often made on comorbidities and physician/patient preferences

First relapse after Ibrutinib


- Is there a place for Idela + R?
 - For patients intolerant or ineligible to Ibrutinib remains an option
 - Ex: Patients with autoimmune thrombocytopenias?
 - In Ibrutinib failure, not recommended
 - Retrospective studies show very poor results
 - Presence of PLCγ2 mutation lead to Idela resistance as well
- Other BTK inhibitors?
 - Similar toxicities
 - Non covalent BCRi may be effective in case of Btk mutations



Quinquenel, Am J Hematol, 2019 Godet, Am J Hematol 2018

What is the best sequence of chemofree?

- Patients will relapse after either I or V+R.
- Then what is the best sequence?
 - There are data of Venetoclax use after Ibrutinib
 - Same response according to the BCRi used
 - If patient reach CR with venetoclax very good
 - Very little data of Ibrutinib after Venetoclax failure
 - Considering mechansims of resistance
 - Btk mutations do not impair response to other therapies
 - But Ibrutinib does not prevent clonal evolution
 - Venetoclax induced resistance mutations target either Bcl-2 mutations or some important pathways that could be more difficult to circumvent




TA Eyre, BJH 2019


Time since best Venetoclax response (months)

Future options – combination of V and I (CLARITY trial) ?

Combining Venetoclax and Ibrutinib in a fixed therapy duration and/or MRD driven Is certainly a very promising option



Primary endpoint : MRD4 (BM) at M12 I + V



Hilmen, ASH 2018

Sequencing therapy in relapsed CLL: conclusions

